Source comparison
Best Tesamorelin for Lipodystrophy: Research Grade Comparison
The table below compares tesamorelin formulations across key quality, sourcing, and application criteria relevant to lipodystrophy research. FDA-Approved (Egrifta) ≥98%, batch-tested by manufacturer Full 44-amino-acid sequence verified pre-release 24 months at
This comparison does not assign a generated winner or score.
- The table below compares tesamorelin formulations across key quality, sourcing, and application criteria relevant to lipodystrophy research.
- FDA-Approved (Egrifta)
- ≥98%, batch-tested by manufacturer
- Full 44-amino-acid sequence verified pre-release
- 24 months at −20°C (unopened)
- Clinical treatment of HIV-associated lipodystrophy
- Gold standard for human use; cost prohibitive for basic research
- Research-Grade (Real Peptides)
- ≥98%, third-party CoA per batch
- Mass spectrometry confirms exact sequence
- 24–36 months at −20°C (unopened)
- Metabolic research, body composition studies, mechanism investigation
- Matches clinical-grade sequencing and purity at research-accessible pricing
- Generic Compounded
- Variable (often 90–95%)
- Rarely verified; relies on raw material supplier claims
- 12–18 months at −20°C (unopened)
- Cost-sensitive applications where slight variability is acceptable
- Lower upfront cost; purity inconsistency introduces confounding variables
- Low-Purity Suppliers
- 85–92% typical
- Not disclosed or verified
- Unknown; often shipped ambient
- Not recommended for research
- High risk of truncated sequences and by-products; results not reproducible
- Here's the honest answer: If your research depends on replicating the visceral fat reductions seen in published tesamorelin trials, purity below 98% introduces uncontrolled variables that make comparisons meaningless. A 92% pure batch contains up to 8% non-functional peptide analogs. Enough to alter effective dose by nearly 10%. For one-time exploratory work, that might be acceptable. For multi-week metabolic studies intended for publication, it's not.